Overview

Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma

Status:
Terminated
Trial end date:
1998-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Current therapies for children with recurrent/progressive high grade gliomas provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of children with recurrent/progressive high grade gliomas. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on children (> 6 months of age) with recurrent/progressive high grade gliomas.
Phase:
Phase 2
Details
Lead Sponsor:
Burzynski Research Institute